ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
A dosimetric and treatment delivery comparisons of the Halcyon and TrueBeam stereotactic plans for one or more brain metastases.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Log file-based treatment efficiency analysis of TrueBeam and Halcyon delivery systems.Journal of applied clinical medical physics · 2026Article
- Dosimetric Evaluation of MR-Guided IMRT and VMAT Techniques for Early-Stage Glottic Cancer: A Pilot Comparative Planning Study.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose of this investigation was to determine if the Halcyon linear accelerator could provide a comparable level of treatment quality and efficiency to the TrueBeam linear accelerator when used for brain stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) in individuals with multiple brain metastases. The goal was to evaluate Halcyon as a potential substitute for TrueBeam. Materials and methods: A review of prior treatments was performed, examining data from 30 individuals (encompassing 64 lesions) who had undergone TrueBeam SRS and SRT procedures. These existing treatment plans were then replanned for the Halcyon platform. Both treatment platforms employed 6 MV-FFF beams; however, the TrueBeam utilized a maximum dose rate of 1400 MU/min, while the Halcyon operated at 800 MU/min. Various dosimetric parameters, such as target coverage, doses to organs at risk, and gradient index, were compared, along with treatment delivery efficiency metrics, including monitor units and beam-on time. Statistical analysis was used for comparisons. Portal dosimetry was implemented for quality assurance. Results: Both platforms achieved comparable target coverage and organ at risk (OAR) sparing, meeting Hypofractionated Treatment Effects in the Clinic (HyTEC), Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC), and the American Association of Physicists in Medicine Task Group 101 (AAPM TG-101) guidelines. Halcyon showed statistically equivalent gros tumor volume/planning target volume (GTV/PTV) doses, but a slightly higher gradient index (clinically insignificant). Beam-on time was longer for Halcyon due to its lower dose rate, but overall treatment time was potentially shorter due to efficient setup. Halcyon exhibited better QA pass rates. Conclusion: Halcyon offers comparable dosimetric quality and treatment efficiency to TrueBeam for brain SRS/SRT. Its streamlined workflow and reduced setup time offer clinical advantages in high-volume centers, despite limitations like the lack of rotational couch correction and lower maximum dose rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.